Abstract
Psoriasis is a common disease that is humiliating for sufferers and for which all treatment is empirical. Cyclosporin was first used successfully in the management of psoriasis in 1979 and has been investigated in controlled studies for more than 10 years. The efficacy and safety of cyclosporin have been established in a large number of double-blind studies involving many hundreds of patients, and a 50 to 75% response rate can be expected in patients with severe chronic plaque disease treated with 2.5 to 5 mg/kg/day for 8 weeks. Regular monitoring is essential but, provided the recommended procedures are adhered to, cyclosporin therapy carries an acceptable risk/benefit ratio.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
